Hepato Care
Viral hepatitis, caused by hepatitis viruses A through E, is a significant public health problem in India. An estimated 40 million people in India have chronic hepatitis B infection, constituting approximately 11% of the estimated global burden. Hepatitis C affects about 12 million patients in India. Both of these blood-borne infections have high risk of chronicity with progression to advanced liver disease and are associated with development of hepatocellular carcinoma, a type of liver cancer, underscoring the need for increased access to high quality, affordable and effective therapy in India. Mylan India launched its Hepato Care division in January 2015 to respond to this public health concern and help meet the unmet medical needs of the patients in India who do not currently have access to critical medicines.
The Hepato Care portfolio includes brand and generic versions of Tenofovir which is approved for the treatment of chronic hepatitis B in adults and pediatric patients 12 years of age and older:
- Viread® (Tenofovir Disoproxil Fumarate 300mg tablets) – a leading antiviral developed by Gilead Sciences and marketed by Mylan
- RicovirTM (Tenofovir Disoproxil Fumarate 300mg tablets) – manufactured and marketed by Mylan
Mylan also offers brand and generic versions of Sofosbuvir which is approved for the treatment of chronic hepatitis C in adults as a component of a combination antiviral treatment regimen:
- Sovaldi® (Sofosbuvir 400mg tablets) – a product developed by Gilead Sciences and marketed by Mylan
- MyHepTM (Sofosbuvir 400mg tablets) – marketed by Mylan
Find a Mylan Product
Search our Indian pharmaceuticals products.
-
Questions?
Get more information on our products, services and Mylan Global Center locations.
Contact Us -
Business Opportunities
Do you have an opportunity or a collaboration idea?
Partner with us
